combination therapy

Phase 3Small molecule

Chong Kun Dang Pharmaceutical

combination therapy is one of 277 small molecule programs targeting Solid Tumor. It is currently in Phase 3.

Indications

Total Trials

Active Trials

276

Competitors

Pipeline

Status by Indication[3][1]

Indication

Solid TumorRecruiting

PneumoniaActive, not recruiting

DysmenorrheaActive, not recruiting

Esophageal Squamous Cell CarcinomaActive, not recruiting

Pulmonary HypertensionNot yet recruiting

Diabetes MellitusRecruiting

Type 2 DiabetesNot yet recruiting

StatinRecruiting

Solid TumorPhase 1

Recruiting

PneumoniaPreclinical

Active, not recruiting

DysmenorrheaPreclinical

Active, not recruiting

Esophageal Squamous Cell CarcinomaPhase 2

Active, not recruiting

Pulmonary HypertensionPhase 3

Not yet recruiting

Diabetes MellitusPhase 3

Recruiting

Type 2 DiabetesPhase 3

Not yet recruiting

StatinPhase 3

Recruiting

Competition

Competitive Landscape

348 competitors in Solid Tumor

#DrugCompanyPhaseTrials

combination therapy

Chong Kun Dang Pharmaceutical

Phase 3

1 2

DATROWAY

Daiichi Sankyo

Preclinical

1 3

Sporanox

SSebela Pharmaceuticals Development LLC

Preclinical

2 4

Proleukin

IIovance Biotherapeutics, Inc.

Preclinical

1 5

Navmi

SSummit Therapeutics

Preclinical

1 6

Paxil

SSebela Pharmaceuticals Development LLC

Preclinical

1 7

Carboplatin AUC-5

Merck & Co.

Preclinical

1 8

PD-1 Inhibitor

Johnson & Johnson

Preclinical

1 9

Soc

Pfizer

Preclinical

1 10

Sacituzumab Govitecan-Hziy

Gilead

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 3Active, not recruiting

Anxiety, Separation

NCT04598230

Post-ApprovalNot yet recruiting

Type 2 Diabetes

NCT06417489

N/ANot yet recruiting

SARS Cov 2 Infection

NCT06610643

Q1 2027

Phase 1Recruiting

Solid Tumor

NCT06251310

Q3 2027

Post-ApprovalNot yet recruiting

Pulmonary Hypertension

NCT07147114

Q4 2027

Phase 2Active, not recruiting

Esophageal Squamous Cell Carcinoma

NCT07142421

Clinical

Trials by Indication[1]

CKD3 trials

CKD-828 (40/5mg) Pharmacokinetic Study

Completed· Chong Kun Dang Pharmaceutical logo

Chong Kun Dang Pharmaceutical·Phase 1·NCT01340131·68 enrolled

CKD-828(80/2.5mg) Pharmacokinetic Study

Completed· Chong Kun Dang Pharmaceutical logo

Chong Kun Dang Pharmaceutical·Phase 1·NCT01246193·65 enrolled

CKD-828(80/2.5mg) Pharmacokinetic Study_2nd

Completed· Chong Kun Dang Pharmaceutical logo

Chong Kun Dang Pharmaceutical·Phase 1·NCT01352689·67 enrolled

Esophageal Cancer1 trial

Study on the Biomarker of First-line Immunotherapy Combined With Chemotherapy in Advanced Esophageal Cancer

Unknown status·SSixth Affiliated Hospital, Sun Yat-sen University·Phase 2·NCT05174156·50 enrolled

Transplant Recipient1 trial

Safety Outcomes of Lower Immunosuppression Versus Traditional Immunosuppression in Heart Transplant Recipients

Completed·NNewark Beth Israel Medical Center·Phase 4·NCT00299221·150 enrolled

Pulmonary Hypertension1 trial

Clinical Trial to Evaluate the Efficacy and Safety in Concomitant Administration of Macitentan and Dapagliflozin in Patients With Heart Failure With Mildly Reduced and Preserved Ejection Fraction (HFmrEF and HFpEF) and Combined Pre- and Post-capillary Pulmonary Hypertension (CpcPH)

Not yet recruiting·GGachon University Gil Medical Center·Phase 4·NCT07147114·64 enrolled

Antithrombotic1 trial

Antithrombotic Strategy for AF Patients With High Risk CAD

Not yet recruiting·YYonsei University·N/A·NCT06866665·1,400 enrolled

15 more indications

Benign Prostatic Hyperplasia1 trial

Comparison Between Alpha Blocker Monotherapy and 5ARI Monotherapy Following Combination Therapy in Benign Prostatic Hyperplasia (BPH)

Completed·SSamsung Medical Center·Phase 4·NCT01301599·308 enrolled

Type 2 Diabetes1 trial

Evaluation of Efficacy and Safety of Combination Therapy of Henagliflozin Proline, Retagliptin and Metformin in New Diagnosed Type 2 Diabetes Patients

Not yet recruiting·PPeking University First Hospital·Phase 4·NCT06417489·160 enrolled

Statin1 trial

Comparison of Moderate-Intensity Statin Plus Ezetimibe vs. High-Intensity Statin for Coronary Plaque Stabilization

Recruiting·KKorea University Anam Hospital·Phase 4·NCT06767345·408 enrolled

Intrahepatic Cholangiocarcinoma1 trial

Combination of Anti-PD-1 Antibody and Chemotherapy for Unresectable Intrahepatic Cholangiocarcinoma

Unknown status·ZZhejiang University·Phase 2·NCT04413734·120 enrolled

Diabetes Mellitus1 trial

Comparison of Pitavastatin Plus Ezetimibe Versus High-Intensity Statin Therapy on Risk of New-Onset Diabetes Mellitus

Recruiting·KKorea University Anam Hospital·Phase 4·NCT06767774·2,000 enrolled

Hypertensive1 trial

Immediate Fracture Risk After Antihypertensive Drug Initiation

Not yet recruiting·—··NCT06964217·10,000,000 enrolled

Dysmenorrhea1 trial

A Preliminary Study on the Efficacy of Danggui Shaoyao San and Cuscuta Chinensis in Patients with Primary Dysmenorrhea

Not yet recruiting·TTaichung Tzu Chi Hospital·N/A·NCT06730282·200 enrolled

Esophageal Squamous Cell Carcinoma1 trial

A Study of Trifluridine/Tipiracil Combined With Anlotinib as Second-line Treatment for Recurrent and Metastatic Esophageal Squamous Cell Carcinoma

Active, not recruiting·FFirst Affiliated Hospital of Zhejiang University·Phase 2·NCT07142421·35 enrolled

Type 1 Diabetes1 trial

Adolescent Type 1 Diabetes Cardio-Renal Intervention Trial

Completed·UUniversity of Cambridge·Phase 3·NCT01581476·443 enrolled

SARS CoV 2 Infection1 trial

Extended Remdesivir Infusion Combined With Nirmatrelvir/Ritonavir for Persistent SARS-CoV-2 Infection in Immunocompromised Patients

Not yet recruiting·NNational Taiwan University Hospital·N/A·NCT06610643·40 enrolled

Multiple Myeloma1 trial

Phase I Trial of Everolimus, Pomalidomide and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma

Terminated·NNew Mexico Cancer Research Alliance·Phase 1·NCT01889420·1 enrolled

Pneumonia1 trial

Turkish Prospective Cohort Study on Carbapenem Resistant Klebsiella Pneumonia Bacteremia

Completed·—··NCT03597841·278 enrolled

Solid Tumor1 trial

A Phase 1a/1b Dose Escalation, Dose Expansion Study of SW-682 in Participants With Advanced Solid Tumors Enriched for Those With Hippo Pathway Mutations

Recruiting·SSpringWorks Therapeutics, Inc.·Phase 1·NCT06251310·186 enrolled

Anxiety, Separation1 trial

Partners in Caring for Anxious Youth

Active, not recruiting·AAnn & Robert H Lurie Children's Hospital of Chicago·Phase 3·NCT04598230·468 enrolled

IBD - Inflammatory Bowel Disease1 trial

Efficacy and Safety of Combined Advanced Targeted Therapy for Inflammatory Bowel Disease: A Prospective, Multicenter, Real-World Study

Completed·XXijing Hospital of Digestive Diseases··NCT07660289·117 enrolled

Sources

References

[1]
ClinicalTrials.gov — 22 trial records for combination therapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — combination therapy compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for combination therapy. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Chong Kun Dang Pharmaceutical company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Chong Kun Dang Pharmaceutical

combination therapy

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q1 2027

Q3 2027

Q4 2027

Trials by Indication[1]

CKD3 trials

Esophageal Cancer1 trial

Transplant Recipient1 trial

Pulmonary Hypertension1 trial

Antithrombotic1 trial

Benign Prostatic Hyperplasia1 trial

Type 2 Diabetes1 trial

Statin1 trial

Intrahepatic Cholangiocarcinoma1 trial

Diabetes Mellitus1 trial

Hypertensive1 trial

Dysmenorrhea1 trial

Esophageal Squamous Cell Carcinoma1 trial

Type 1 Diabetes1 trial

SARS CoV 2 Infection1 trial

Multiple Myeloma1 trial

Pneumonia1 trial

Solid Tumor1 trial

Anxiety, Separation1 trial

IBD - Inflammatory Bowel Disease1 trial

References

Drug Info

Quick Facts

Related News